Results 261 to 270 of about 438,789 (339)

Ecological study of social organization in the Great Tit, Parus major L

, 1979
Takashi Saitou
openalex   +2 more sources

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING‐Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy

Arthritis &Rheumatology, EarlyView.
Objective The objective was to report the safety and efficacy of an anti‐IFNAR1 antibody (anifrolumab) in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who presented with vasculitic ulcers and systemic inflammation refractory to JAK inhibition (JAKi) and to the interferon‐β–neutralizing monoclonal antibody dazukibart ...
Sara Alehashemi, Bjoern Buehring, Adriana A. de Jesus, Sachin Gaurav, Andre Rastegar, Alexi Baumgardner, Kip Friend, Oluwatobi T. Arisa, William D. Figg, Danielle Fink, Douglas B. Kuhns, Ben Colton, Cody J. Peer, Raphaela Goldbach‐Mansky   +13 more
wiley   +1 more source

A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study. [PDF]

Clin Exp Med
Yingyounyong S, Ngamjanyaporn P, Pisitkun P, Boonnak K, Suangtamai T, Thongpradit S, Rotjanapan P.   +6 more
europepmc   +1 more source

Aberrant glycosylation of IgG in children with active lupus nephritis alters podocyte metabolism and causes podocyte injury

Arthritis &Rheumatology, Accepted Article.
Background Podocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes and decreased nephrin production.
Rhea Bhargava, Rohit Upadhyay, Cong Zhao, Prasad Katakam, Scott Wenderfer, Jing Chen, Hua He, Richard Cummings, Maria G. Tsokos, George C. Tsokos   +9 more
wiley   +1 more source

Rapid and Economic Baculovirus Titer Determination Using a Novel Transgenic Sf9-QE Cell Line. [PDF]

Insects
Moon HJ, Kim HJ, Lee DH, Mun SY, Woo SD.
europepmc   +1 more source

Food and food consumption of nestling tits, Parus major minor and Parus varius varius, in the ever-green broad leaved forests in northern Kyushu

, 1979
Kazuhiro Eguchi
openalex   +2 more sources

Differences in dynamics of specific anti‐nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective The presence of anti‐nuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti‐dsDNA is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA serum levels are associated ...
Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Cooney Laura, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W.J. Huizinga, Cees van Kooten, René E.M. Toes, Betty Diamond, Y.K. Onno Teng, Jolien Suurmond   +16 more
wiley   +1 more source

Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers. [PDF]

Ann Fam Med
Williams AL, Newman RS.
europepmc   +1 more source

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Arthritis &Rheumatology, Accepted Article.
Objective Despite availability of biologics and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital   +13 more
wiley   +1 more source

Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities. [PDF]

Sci Rep
Park ES, Yoshikawa T, Tani H, Kimura M, Kaku Y, Imaoka K, Maeda K, Saijo M, Morikawa S.   +8 more
europepmc   +1 more source